Henry Lowman
Lowman comes to the role after joining CytomX in September 2010, as VP of research.
In his new role, he will lead research and development activities to advance the proteolytically-activated antibodies specialists’ Probody candidates.
“Henry’s tremendous depth of experience in antibody engineering and therapeutic development has enabled him to make unique contributions to CytomX over the past year,” said Sean McCarthy, D. Phil., chief executive officer of CytomX.
“His previous successes in the engineering of high value clinical candidates and marketed products will continue to prove invaluable as we gain even greater momentum with the Probody platform.”